Waldenstrom macroglobulinemia: Genomic aberrations and treatment

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Scopus citations


Waldenström macroglobulinemia (WM) is a rare, indolent, and monoclonal immunoglobulin M-associated lymphoplasmacytic disorder with unique clinicopathologic characteristics. Over the past decade, remarkable progress has occurred on both the diagnostic and therapeutic fronts in WM. A deeper understanding of the disease biology emanates from the seminal discoveries of myeloid differentiation primary response 88 (MYD88) L265P somatic mutation in the vast majority of cases and C-X-C chemokine receptor, type 4, mutations in about a third of patients. Although WM remains an incurable malignancy, and the indications to initiate treatment are largely unchanged, the therapeutic armamentarium continues to expand. Acknowledging the paucity of high-level evidence from large randomized controlled trials, herein, we evaluate the genomic aberrations and provide a strategic framework for the management in the frontline as well as the relapsed/refractory settings of symptomatic WM.

Original languageEnglish (US)
Title of host publicationCancer Treatment and Research
PublisherKluwer Academic Publishers
Number of pages41
StatePublished - 2016

Publication series

NameCancer Treatment and Research
ISSN (Print)0927-3042


  • BTK inhibitors
  • CXCR4
  • IgM
  • MYD88
  • Waldenstrom’s macroglobulinemia

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Waldenstrom macroglobulinemia: Genomic aberrations and treatment'. Together they form a unique fingerprint.

Cite this